The purpose of the Organic Synthesis Core Facility (OSCF) is to provide MSKCC investigators with a fully equipped facility complete with chemistry instrumentation, GMP infrastructure, and staff with the ability to interact with non-chemists as well as chemists, in order to carry out the requested chemical synthesis and consultation. OSCF also assists investigators with pre-clinical and clinical projects. Services are focused on the following: The chemical synthesis of compounds which are not readily available. This is accomplished using established synthetic protocols or by developing new synthetic methodologies. The synthesis of assay development tools and reagents: a) fluorescently labeled compounds, b) affinity labeled compounds, and c) cross linker-tethered molecules. Cold-labeled (13C, 2H, 15N) and radio-labeled (3H, 14C, 1251, 32P, ...etc.) compounds and precursors for preclinical and clinical pharmacological studies which cannot be addressed by the shared Cyclotron- Radiochemistry Core facility. To perform large-scale -cGMP or non-cGMP- chemical syntheses of compounds with demonstrated activity in primary bioassays for preclinical, phase I and II clinical studies (i.e. Le y, Globo H, which are penta- and hexa-carbohydrate antigen vaccine constructs, Cur-61414, peptidyl-Luciferin enzyme activity beacons, and Marimastat) in order to provide sufficient quantities for continued testing. The synthesis of modified and unmodified compounds in amounts that permit their availability for in vitro and in vivo assays and for secondary assays. For example, modifications are introduced to improve solubility, affinity, and specificity. Design, synthesis, and generation of libraries of structurally related compounds based on confirmed hits; library optimization through structure-activity relationships (SAR) identified in a pharmacophore using directed library synthesis and structure-guided design in order to enhance targeting, specificity, and bioavailability while minimizing toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-47
Application #
8375215
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2012
Total Cost
$180,706
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404
Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :
Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712
Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118
Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210
Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599
Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990
Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846
Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209
He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125

Showing the most recent 10 out of 7561 publications